These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection. Takanashi A; Pouton CW; Al-Wassiti H Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979 [TBL] [Abstract][Full Text] [Related]
6. Chemistry of Lipid Nanoparticles for RNA Delivery. Eygeris Y; Gupta M; Kim J; Sahay G Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635 [TBL] [Abstract][Full Text] [Related]
7. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. Peng L; Renauer PA; Ökten A; Fang Z; Park JJ; Zhou X; Lin Q; Dong MB; Filler R; Xiong Q; Clark P; Lin C; Wilen CB; Chen S Cell Rep Med; 2022 May; 3(5):100634. PubMed ID: 35561673 [TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV Valentin A; Bergamaschi C; Rosati M; Angel M; Burns R; Agarwal M; Gergen J; Petsch B; Oostvogels L; Loeliger E; Chew KW; Deeks SG; Mullins JI; Pavlakis GN; Felber BK Front Immunol; 2022; 13():945706. PubMed ID: 35935984 [TBL] [Abstract][Full Text] [Related]
9. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria. Meulewaeter S; Aernout I; Deprez J; Engelen Y; De Velder M; Franceschini L; Breckpot K; Van Calenbergh S; Asselman C; Boucher K; Impens F; De Smedt SC; Verbeke R; Lentacker I J Control Release; 2024 Jun; 370():379-391. PubMed ID: 38697317 [TBL] [Abstract][Full Text] [Related]
10. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512 [TBL] [Abstract][Full Text] [Related]
11. STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2. Zhang Y; Yan J; Hou X; Wang C; Kang DD; Xue Y; Du S; Deng B; McComb DW; Liu SL; Zhong Y; Dong Y Nano Lett; 2023 Apr; 23(7):2593-2600. PubMed ID: 36942873 [TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311 [TBL] [Abstract][Full Text] [Related]
13. mRNA-LNP vaccination-based immunotherapy augments CD8 Qiu K; Duan X; Mao M; Song Y; Rao Y; Cheng D; Feng L; Shao X; Jiang C; Huang H; Wang Y; Li H; Chen X; Wu S; Luo D; Chen F; Peng X; Zheng Y; Wang H; Liu J; Zhao Y; Song X; Ren J NPJ Vaccines; 2023 Sep; 8(1):144. PubMed ID: 37773254 [TBL] [Abstract][Full Text] [Related]
14. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Tombácz I; Laczkó D; Shahnawaz H; Muramatsu H; Natesan A; Yadegari A; Papp TE; Alameh MG; Shuvaev V; Mui BL; Tam YK; Muzykantov V; Pardi N; Weissman D; Parhiz H Mol Ther; 2021 Nov; 29(11):3293-3304. PubMed ID: 34091054 [TBL] [Abstract][Full Text] [Related]
16. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810 [TBL] [Abstract][Full Text] [Related]
17. Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy. Jiang Y; Zhang Y; Liu C; Liu J; Xue W; Wang Z; Li X J Control Release; 2024 Apr; 368():663-675. PubMed ID: 38492862 [TBL] [Abstract][Full Text] [Related]
18. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery. Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702 [TBL] [Abstract][Full Text] [Related]
19. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. Mao S; Li S; Zhang Y; Long L; Peng J; Cao Y; Mao JZ; Qi X; Xin Q; San G; Ding J; Jiang J; Bai X; Wang Q; Xu P; Xia H; Lu L; Xie L; Kong D; Zhu S; Xu W Nano Today; 2023 Feb; 48():101730. PubMed ID: 36570700 [TBL] [Abstract][Full Text] [Related]